Department of PET Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Department of Radiology, Guangzhou First People's Hospital, Guangzhou, China.
Korean J Radiol. 2021 Mar;22(3):425-434. doi: 10.3348/kjr.2020.0211. Epub 2020 Nov 19.
To investigate the potential value of F-fluorodeoxyglucose (FDG) PET/CT in predicting the survival of patients with primary tracheal malignant tumors.
An analysis of FDG PET/CT findings in 37 primary tracheal malignant tumor patients with a median follow-up period of 43.2 months (range, 10.8-143.2 months) was performed. Cox proportional hazards regression analyses were used to assess the associations between quantitative F-FDG PET/CT parameters, other clinic-pathological factors, and overall survival (OS). A risk prognosis model was established according to the independent prognostic factors identified on multivariate analysis. A survival curve determined by the Kaplan-Meier method was used to assess whether the prognosis prediction model could effectively stratify patients with different risks factors.
The median survival time of the 37 patients with tracheal tumors was 38.0 months, with a 95% confidence interval of 10.8 to 65.2 months. The 3-year, 5-year and 10-year survival rate were 54.1%, 43.2%, and 16.2%, respectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value, age, pathological type, extension categories, and lymph node stage were included in multivariate analyses. Multivariate analysis showed MTV ( = 0.011), TLG ( = 0.020), pathological type ( = 0.037), and extension categories ( = 0.038) were independent prognostic factors for OS. Additionally, assessment of the survival curve using the Kaplan-Meier method showed that our prognosis prediction model can effectively stratify patients with different risks factors ( < 0.001).
This study shows that F-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with an MTV > 5.19, a TLG > 16.94 on PET/CT scans, squamous cell carcinoma, and non-E1 were more likely to have a reduced OS.
探讨 F-氟代脱氧葡萄糖（FDG）PET/CT 预测原发性气管恶性肿瘤患者生存的潜在价值。
对 37 例原发性气管恶性肿瘤患者的 FDG PET/CT 检查结果进行分析，中位随访时间为 43.2 个月（范围 10.8-143.2 个月）。采用 Cox 比例风险回归分析评估定量 F-FDG PET/CT 参数、其他临床病理因素与总生存期（OS）之间的相关性。根据多因素分析确定的独立预后因素建立风险预后模型。采用 Kaplan-Meier 法绘制生存曲线，评估预后预测模型是否能有效分层不同危险因素患者。
37 例气管肿瘤患者的中位生存时间为 38.0 个月，95%置信区间为 10.8-65.2 个月。3 年、5 年和 10 年生存率分别为 54.1%、43.2%和 16.2%。代谢肿瘤体积（MTV）、总病变糖酵解（TLG）、最大标准化摄取值、年龄、病理类型、侵犯范围和淋巴结分期均纳入多因素分析。多因素分析显示 MTV（ = 0.011）、TLG（ = 0.020）、病理类型（ = 0.037）和侵犯范围（ = 0.038）是 OS 的独立预后因素。此外，Kaplan-Meier 法评估生存曲线显示，我们的预后预测模型可有效分层不同风险因素的患者（ < 0.001）。
本研究表明 F-FDG PET/CT 可预测原发性气管恶性肿瘤患者的生存情况。MTV＞5.19、TLG＞16.94、鳞癌和非 E1 患者 OS 更短。
